249890-37-7

Basic information

• Product Name: (1S,5R,7R,2'R,S,3'R,S)-7-hydroxy-6-[(E,Z)-3'-hydroxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one
• Synonyms: (1S,5R,7R,2'R,S,3'R,S)-7-hydroxy-6-[(E,Z)-3'-hydroxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one
• CAS NO: 249890-37-7
• Molecular Weight: 402.488
• Mol File: 249890-37-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1S,5R,7R,2'R,S,3'R,S)-7-hydroxy-6-[(E,Z)-3'-hydroxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,5R,7R,2'R,S,3'R,S)-7-hydroxy-6-[(E,Z)-3'-hydroxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one(249890-37-7)
• EPA Substance Registry System: (1S,5R,7R,2'R,S,3'R,S)-7-hydroxy-6-[(E,Z)-3'-hydroxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one(249890-37-7)

Safety Data

• Hazardous Substances Data: 249890-37-7(Hazardous Substances Data)

Upstream product

• 249890-39-9 (1S,5S,6R,7R)-6,7-epoxy-6-hydroxymethyl-2-oxabicyclo[3.3.0]octan-3-one 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 15097-38-8 (carbobenzyloxymethylene)triphenylphosphorane 
• 51260-12-9 (1S,5S)-3-oxo-2-oxabicyclo<3.3.0>oct-6-en-6-carbaldehyde 
• 62158-44-5 (1S,5R)-6-hydroxymethyl-2-oxabicyclo[3.3.0]oct-6-en-3-one 
• 66-25-1 hexanal 
• 249890-38-8 (1S,5S,6S,7R)-6,7-epoxy-6-[(E)-2'-carbobenzyloxy-1'-vinyl]-2-oxabicyclo[3.3.0]octan-3-one 

Downstream Products

• 249890-40-2 (1S,5R,7R,2'R,S,3'R,S)-7-[(tert-butyl)dimethylsiloxy]-6-[(E,Z)-3'-(tert-butyl)dimethylsiloxyoct-2'-carbobenzyloxy-1'-ylidene]-2-oxabicyclo[3.3.0]octan-3-one 

Relevant articles and documents

Enantioselective synthesis of 12-epi-PGF(2α) and 12,15-diepi-PGF(2α)

An enantioselective synthesis of 12-epi-PGF(2α) (3) and 12,15-diepi- PGF(2α) (4), PG-like compounds that are probably generated in vivo by nonenzymatic, free-radical-induced peroxidation of arachidonic acid, has been achieved starting from the commercially available Corey lactone (9). The key strategy involves SmI2 reduction of the γ,δ-epoxy-α,β-unsaturated ester 7, followed by in situ trapping with hexanal; subsequent hydrogenation and decarboxylation affords the stereoselective construction of the lower side chain. This new method is expected to provide a convenient access to various PG-like isoprostanes derived from oxidation of arachidonic acid and cis- 4,7,10,13,16,19-docosahexaenoic acid.